Overview

This trial is active, not recruiting.

Condition alzheimer's disease
Treatments bryostatin 1, placebo
Phase phase 2
Sponsor Neurotrope Bioscience, Inc.
Start date November 2015
End date January 2017
Trial size 150 participants
Trial identifier NCT02431468, NTRP-101-202

Summary

This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer's disease. The study is 15 weeks in duration, including a safety and efficacy evaluation 30 days after the last dose of study drug.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Arm
(Experimental)
Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
bryostatin 1 bryostatin
The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
(Experimental)
Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
bryostatin 1 bryostatin
The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
(Placebo Comparator)
Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.
placebo
The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution.

Primary Outcomes

Measure
Safety: Treatment emergent Adverse Events and Serious Adverse Events
time frame: Primary analysis after 12 weeks of treatment
Efficacy: Change from baseline in Severe Impairment Battery (SIB)
time frame: Primary analysis after 12 weeks of treatment

Eligibility Criteria

Male or female participants from 55 years up to 85 years old.

Inclusion Criteria: - Written informed consent from caregiver and subject (if possible) or legally acceptable representative if different from caregiver - Male and female subjects 55-85 years of age inclusive - Cognitive deficit present for at least 2 years that meet the diagnostic criteria for probable Alzheimer's - Mini Mental State Exam (MMSE-2) score of 4-15 - Patients must be able to perform at least one item on the Severe Impairment Battery Scale - Neuroimaging (computerized tomography (CT) or Magnetic Resonance Imaging (MRI)) within the last 24 months consistent with a diagnosis of probable Alzheimer's disease (AD) - Reliable caregiver(s) or informant(s) who attends the subject at least an average of 3 hours or more per day for 3 or more days per week - Adequate vision and motor function to comply with testing - If taking drugs approved for treatment of Alzheimer's disease (e.g. cholinesterase inhibitors, memantine), must be on a stable dose for at least 3 months prior to entry into study and the dose must not change during the study unless a change is required due to an adverse event or a clinically significant change in the patient's status. Exclusion Criteria: - Dementia due to any condition other than AD, including vascular dementia (Rosen-modified Hachinski lschemic score ≥ 5) - Evidence of significant central nervous system (CNS) vascular disease on previous neuroimaging including but not limited to: cortical stroke, multiple infarcts, localized single infarcts in the thalamus, angular gyrus, multiple lacunar infarcts or extensive white matter injury - Clinically significant neurologic disease or condition other than AD, such as cerebral tumor, chronic subdural fluid collections, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus, or any other diagnosis that could interfere with assessment of safety and efficacy - Evidence of clinically significant unstable cardiovascular, pulmonary, renal, hepatic, gastrointestinal, neurologic, or metabolic disease within the 6 months prior to enrollment - Poorly controlled diabetes, at the discretion of the Principal Investigator - Creatinine clearance (CL) of <45ml/min - Use of an active Alzheimer's vaccine within 2 years prior to screening - Use of a monoclonal antibody for treatment of AD within 1 year prior to screening - Any medical or psychiatric condition that is likely to require initiation of additional medication or surgical intervention during the course of the study - Use of an investigational drug within 30 days prior to screening - Prior exposure to bryostatin, or known sensitivity to bryostatin or any ingredient in the study drug - Any other concurrent medical condition, which in the opinion of the PI makes the subject unsuitable for the clinical study

Additional Information

Official title A Randomized, Double-Blind,Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
Description This study will enroll 150 moderately severe to severe Alzheimer's disease subjects. Subjects will be randomly assigned 1:1:1 to treatment with two different doses of bryostatin 1 or placebo. The primary analysis will take place after 12 weeks of treatment (7 doses).
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Neurotrope Bioscience, Inc..